Tiotidine, a histamine H2 receptor inverse agonist that binds with high affinity to an inactive G-protein-coupled form of the receptor. Experimental support for the cubic ternary complex model

Molecular Pharmacology

Volumn 64, Issue 2, 2003, Pages 512-520

  Monczor, Federico ^a,b   Fernández, Natalia ^a,b,c   Legnazzi, Bibiana Lemos ^a   Riveiro, Maria Eugenia ^a   Baldi, Alberto ^b,c   Shayo, Carina ^a,b,c   Davio, Carlos ^a,b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Consejo Nac Invest Cie Tecnicas ^*  (Argentina)

^c INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; G PROTEIN COUPLED RECEPTOR; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HISTAMINE H2 RECEPTOR; HISTAMINE H2 RECEPTOR AGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; TIOTIDINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG USE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CIMETIDINE; COS CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTAMINE AGONISTS; HISTAMINE H2 ANTAGONISTS; HUMANS; MODELS, BIOLOGICAL; RECEPTORS, HISTAMINE H2; TRANSFECTION; TRITIUM; TUMOR CELLS, CULTURED; U937 CELLS;

EID: 0042343718     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.64.2.512     Document Type: Article

References (32)

1. Alewijnse AE, Timmerman H, Jacobs EH, Smit MJ, Roovers E, Cotecchia S, and Leurs R (2000) The effect of mutations in the DRY motif on the constitutive activity and structural instability of the histamine H2 receptor. Mol Pharmacol 57:890-898.
2. 3H]-tiotidine a specific ligand for the H2-receptor? Pharmacology 32:241-247.
3. Bouaboula M, Parrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, et al. (1997) A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. J Biol Chem 272:22330-22339.
4. 3H-Naloxone benzoylhydrazone binding in MOR-1-transfected Chinese hamster ovary cells: Evidence for G-protein-dependent antagonist binding. J Pharmacol Exp Ther 286:376-381.
5. Chidiac P, Hebert TE, Valiquette M, Dennis M, and Bouvier M (1994) Inverse agonist activity of β-adrenergic agonists. Mol Pharmacol 45:490-499.
6. 2 histamine receptors in histiocytic lymphoma cell line U937. Inflamm Res 44:S72-S73, 1995a.
7. 2 histamine receptors in N-nitroso-N-methylurea (NMU)-induced carcinomas with atypical coupling to signal transducers. Biochem Pharmacol 50:91-96.
8. De Léan A, Stadel JM, and Lefkowitz RJ (1980) A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J Biol Chem 255:7108-7117.
9. Del Valle J and Gantz I (1997) Novel insights into histamine H2 receptor biology. Am J Physiol 273:G987-G996.
10. Fernández N, Monczor F, Lemos B, Notcovich C, Baldi A, Davio C, and Shayo C (2002) Reduction of G protein-coupled receptor kinase 2 expression in U-937 cells attenuates H2 histamine receptor desensitization and induces cell maturation. Mol Pharmacol 62:1506-1514.
11. Hall A and Strange PG (1997) Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors. Br J Pharmacol 121:731-736.
12. Hilser VJ, Dowdy D, Oas TG, and Freire E (1998) The structural distribution of cooperative interactions in proteins: analysis of the native state ensemble. Proc Natl Acad Sci USA 18:9903-9908.
13. Kenakin T, Morgan P, and Lutz M (1995) On the importance of the "antagonist assumption" to how receptors express themselves. Biochem Pharmacol 50:17-26.
14. Kjelsberg MA, Cotecchia S, Ostrowski J, Caron MG, and Lefkowitz RJ (1992) Constitutive activation of the α1β-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. J Biol Chem 267:1430-1433.
15. Lemos B, Shayo C, Monczor F, Martin ME, Fernandez N, Brodsky A, Baldi A, and Davio C (2000) Rapid desensitization and slow recovery of cyclic AMP response mediated by histamine H2 receptors in U-937 cell line. Biochem Pharmacol 60:159-166.
16. Leurs R, Hoffmann M, Alewijnse AE, Smit MJ, and Timmerman H (2002) Methods to determine the constitutive activity of histamine H2 receptors. Methods Enzymol 343:405-416.
17. Milligan G (1996) The stoichiometry of expression of protein components of the stimulatory adenylyl cyclase cascade and the regulation of information transfer. Cell Signal 8:87-96.
18. Monczor F, Legnazzi BL, Rivera E and Davio C. Tiotidine, a classical H2-antagonist, presents characteristics of an inverse agonist in U937 cell line. Inflamm Res 47:S42-43, 1998.
19. Munson PJ and Rodbard D (1980) Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107:220-239.
20. Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, Dumont J, and Vassart G (1993) Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature (Lond) 865:649-651.
21. Rising TJ and Norris DB (1985) Histamine H2 receptor radioligand studies, in Frontiers in Histamine Research (Ganellin CR and Schwartz JC eds) pp 61-67, Pergamon, Oxford.
22. 1b adrenergic receptor subtypes. Mol Pharmacol 56:858-866.
23. Samama P, Cotecchia S, Costa T, and Lefkowitz RJ (1993) A mutation-induced activated state of the β2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268:4625-4636.
24. 2 receptor desensitization. Involvement of a select array of G protein-coupled receptor kinases. Mol Pharmacol 60:1049-1056.
25. Shenker A, Laue L, Kosugi S, Merendino JJ Jr, Minegishi T, and Cutler GB Jr (1993) A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature (Lond) 365:652-654.
26. Smit MJ, Leurs R, Alewijnse AE, Blauw J, Van Nieuw Amerongen GP, Van De Vrede Y, Roovers E, and Timmerman H (1996) Inverse agonism of histamine H2 antagonists accounts for up-regulation of spontaneously active histamine H2 receptors. Proc Natl Acad Sci USA 93:6802-6807.
27. van der Goot H, Bast A, and Timmerman H (1991) Structural requirements for histamine H2 agonists and H2 antagonists, in Handbook of Experimental Pharmacology, Vol 97 (Arrang J-M, Uvnäs Bed) pp 573-748, Springer-Verlag, Berlin.
28. van der Goot H and Timmerman H (2000) Selective ligands as tools to study histamine receptors. Eur J Med Chem 35:5-20.
29. Weiss JM, Morgan PH, Lutz MW, and Kenakin TP (1996a) The cubic ternary complex receptor-occupancy model. I. Model description. J Theor Biol 178:151-167.
30. Weiss JM, Morgan PH, Lutz MW, and Kenakin TP (1996b) The cubic ternary complex receptor-occupancy model. II. Understanding apparent affinity. J Theor Biol 178:169-182.
31. Weiss JM, Morgan PH, Lutz MW, and Kenakin TP (1996c) The cubic ternary complex receptor hyphen occupancy model. III. Resurrecting efficacy. J Theor Biol 181:381-397.
32. Westphal RS and Sanders-Bush E (1994) Reciprocal binding properties of 5HT2c receptor agonists and antagonists. Mol Pharmacol 46:937-942.